Skip to main content

Table 3 Clinical characteristics of the main non-AIDS defining cancer (NADC) identified

From: Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico

NADC —N (%) HL—36 (28.3) Anal—16 (12.6) Germinal—13 (10.2) Head/neck—9 (7.1) Lung—2 (1.6) Skin—7 (5.5) Breast—7 (5.5) Vulvar/vaginal—13 (10.2)a
Age (years)b 39.9 ± 9.1 42.2 ± 7.8 33.4 ± 5.5 49.1 ± 8.1 47 and 51 57.3 ± 11.3 43.2 ± 1.9 50.3 ± 10.8
CD4 (cells/µL)c 162 (106, 302) 270 (152, 457) 117 (33, 421) 214 (103, 513) 219 and 231 369 (249, 593) 890 (472, 927) 481 (371, 805)
Viral load (copies/mL)c < 40 (< 40, 2168) < 40 (< 40, 78,000) 51,930 (51, 750,000) 17,970 (2475, 34,205) < 40 and 21,300 < 40 (< 40, 16,300) < 40 (< 40, 50) < 40 (< 40, 55)
Follow-up (weeks)cd 8.9 (2.7, 31) 13.9 (5.8, 30.2) 13.6 (4.3, 29.1) 10.7 (8.5, 22.8) 1.7 and 5.9 22.1 (6.5, 49.6) 9.7 (7.4, 26.8) 9.2 (3.2, 26.9)
Alive 30 (83.3) 9 (56.2) 0 8 (88.9) 1 (50) 6 (85.7) 6 (85.7) 11 (84.6)
Dead 6 (16.7) 7 (43.8) 13 (100) 1 (50) 1 (50) 1 (43.3) 1 (43.3) 2 (15.4)
  1. HL, Hodgkin lymphoma
  2. aThere were 13 patients with 14 vulvar/vaginal cancers (one patient had both)
  3. bMean ± standard deviation (SD)
  4. cMedian (InterQuartile Range [IQR])
  5. dFollow-up was from NADC diagnosis until last hospital visit